Locus Coeruleus Neurons In Dementia With Lewy Bodies is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
The locus coeruleus (LC) is the primary source of norepinephrine in the central nervous system and plays crucial roles in attention, arousal, and autonomic function. In dementia with Lewy bodies (DLB), the second most common neurodegenerative dementia after Alzheimer's disease, LC neurons undergo significant degeneration. This loss contributes to the characteristic neuropsychiatric symptoms of DLB, including fluctuating cognition, visual hallucinations, and REM sleep behavior disorder. [1]
The locus coeruleus is located: [2]
LC neurons project to virtually all brain regions: [3]
Forebrain:
Cortex:
Brainstem and spinal cord:
DLB is classified as a synucleinopathy with: [4]
LC dysfunction directly contributes to:
Cholinesterase inhibitors: First-line for cognitive symptoms (e.g., rivastigmine)
Dopaminergic agents: For parkinsonism
Antipsychotics: USE WITH EXTREME CAUTION
Non-pharmacological:
Noradrenergic agents:
Deep brain stimulation: LC or pontine targets (experimental)
Alpha-synuclein targeting:
Neuroprotective strategies:
The study of Locus Coeruleus Neurons In Dementia With Lewy Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. [Staging of brain pathology related to sporadic Parkinson's disease](https://doi.org/10.1016/s0197-4580(02). Staging of brain pathology related to sporadic Parkinson's disease. 2003. ↩︎
Weinshenker D. The rising prevalence of dementia with Lewy bodies: implications for the noradrenergic system. The rising prevalence of dementia with Lewy bodies: implications for the noradrenergic system. 2022. ↩︎
Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. 2021. ↩︎
Outeiro TF, Koss DJ, Erskine D, et al. Dementia with Lewy bodies: an update and outlook. Dementia with Lewy bodies: an update and outlook. 2019. ↩︎